EYPT Logo

EyePoint Pharmaceuticals, Inc. (EYPT) 

NASDAQ$6.52
Market Cap
$448.11M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
26 of 924
Rank in Industry
21 of 527

EYPT Insider Trading Activity

EYPT Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$20,755,667667
Sells
$383,745333

Related Transactions

Cormorant Asset Management, LP10 percent owner2$20.57M0$0$20.57M
Zaderej Karen L.director1$99,7500$0$99,750
ANDO GORANdirector1$39,7500$0$39,750
Lurker Nancydirector1$25,0030$0$25,003
DICICCO WENDY Fdirector1$19,9970$0$19,997
GUYER DAVID Rdirector0$03$383,745$-383,745

About EyePoint Pharmaceuticals, Inc.

EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the â€¦

Insider Activity of EyePoint Pharmaceuticals, Inc.

Over the last 12 months, insiders at EyePoint Pharmaceuticals, Inc. have bought $20.76M and sold $383,745 worth of EyePoint Pharmaceuticals, Inc. stock.

On average, over the past 5 years, insiders at EyePoint Pharmaceuticals, Inc. have bought $22.43M and sold $43.05M worth of stock each year.

Highest buying activity among insiders over the last 12 months: Cormorant Asset Management, LP (10 percent owner) — $20.57M. Zaderej Karen L. (director) — $99,750. ANDO GORAN (director) — $39,750.

The last purchase of 5,000 shares for transaction amount of $39,750 was made by ANDO GORAN (director) on 2024‑08‑21.

List of Insider Buy and Sell Transactions, EyePoint Pharmaceuticals, Inc.

2024-08-21PurchaseANDO GORANdirector
5,000
0.0082%
$7.95$39,750-8.56%
2024-08-20PurchaseDICICCO WENDY Fdirector
2,567
0.0048%
$7.79$19,997+7.38%
2024-08-19PurchaseZaderej Karen L.director
12,500
0.0235%
$7.98$99,750+4.22%
2024-08-16PurchaseLurker Nancydirector
3,173
0.0057%
$7.88$25,003+4.16%
2024-07-12SaleGUYER DAVID Rdirector
11,625
0.0274%
$10.06$116,995-18.88%
2024-06-03SaleGUYER DAVID Rdirector
11,625
0.0233%
$10.30$119,705-13.16%
2024-05-14SaleGUYER DAVID Rdirector
11,625
0.0227%
$12.65$147,045-30.24%
2024-05-06PurchaseCormorant Asset Management, LP10 percent owner
850,000
1.8064%
$11.86$10.08M-22.28%
2024-04-18PurchaseCormorant Asset Management, LP10 percent owner
581,765
1.2029%
$18.03$10.49M-50.00%
2024-02-02SaleJones David ScottSVP & Chief Commercial Officer
209
0.0007%
$28.49$5,954-67.70%
2024-01-26SaleJones David ScottSVP & Chief Commercial Officer
26,017
0.0509%
$25.38$660,370-64.41%
2024-01-26SalePaggiarino Dario A.Chief Medical Officer
49,325
0.0975%
$25.66$1.27M-64.41%
2024-01-25SaleJones David ScottSVP & Chief Commercial Officer
600
0.0012%
$25.00$15,000-62.09%
2024-01-25SalePaggiarino Dario A.Chief Medical Officer
600
0.0012%
$25.00$15,000-62.09%
2024-01-24SaleLurker NancyExecutive Vice Chair
29,956
0.0887%
$24.98$748,250-60.48%
2024-01-24SaleJones David ScottSVP & Chief Commercial Officer
11,300
0.0335%
$25.01$282,621-60.48%
2024-01-24SalePaggiarino Dario A.Chief Medical Officer
11,251
0.0334%
$25.01$281,415-60.48%
2024-01-23SaleLurker NancyExecutive Vice Chair
5,044
0.0144%
$24.97$125,950-61.98%
2024-01-23SaleJones David ScottSVP & Chief Commercial Officer
900
0.0026%
$25.00$22,500-61.98%
2024-01-23SalePaggiarino Dario A.Chief Medical Officer
5,135
0.0146%
$25.00$128,375-61.98%
Total: 82
*Gray background shows transactions not older than one year

Insider Historical Profitability

<0.0001%
Cormorant Asset Management, LP10 percent owner
8325000
12.1128%
$54.28M60<0.0001%
Lurker Nancydirector
97635
0.1421%
$636,580.2044<0.0001%
Zaderej Karen L.director
16500
0.024%
$107,580.0010
ANDO GORANdirector
13150
0.0191%
$85,738.0010
DICICCO WENDY Fdirector
9967
0.0145%
$64,984.8410
*Gray background shows insiders who have made transactions during last year

Historical Insider Profitability vs. Competitors

$14,527,743
76
38.40%
$447.93M
$84,871,118
57
17.71%
$412.59M
$24,384,691
42
-30.27%
$455.92M
$54,828,550
26
-13.88%
$493.09M
$26,923,982
20
-17.22%
$407.13M

EYPT Institutional Investors: Active Positions

Increased Positions95+77.87%22M+37.34%
Decreased Positions49-40.16%6M-10.54%
New Positions30New7MNew
Sold Out Positions23Sold Out2MSold Out
Total Postitions168+37.7%74M+26.8%

EYPT Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Cormorant Asset Management, Lp$52,198.0012.24%8.32M00%2024-12-31
Suvretta Capital Management, Llc$42,530.009.98%6.78M+2M+31.05%2024-12-31
Adage Capital Partners Gp, L.L.C.$36,053.008.46%5.75M+2M+51.66%2024-12-31
Blackrock, Inc.$33,114.007.77%5.28M+1M+27.1%2024-12-31
Franklin Resources Inc$25,943.006.09%4.14M+125,519+3.13%2024-12-31
Vanguard Group Inc$23,846.005.59%3.8M+755,045+24.77%2024-12-31
Federated Hermes, Inc.$23,246.005.45%3.71M+2M+92.73%2024-12-31
Tcg Crossover Management, Llc$22,399.005.25%3.57M+3M+287.31%2024-12-31
Ra Capital Management, L.P.$19,950.004.68%3.18M+3MNew2024-12-31
Citadel Advisors Llc$15,467.003.63%2.47M+1M+75.28%2024-12-31

Financial Ratios

Summary
Comparison with Competitors

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.